Sleep apnea (alternatively sleep apnoea) is a common sleep disorder characterized by brief interruptions of breathing during sleep. These episodes, called apneas, last 10 seconds or more and occur repeatedly throughout the night. People with sleep apnea partially awaken as they struggle to breathe, but in the morning they may not be aware of the disturbances in their sleep. Nearly 40 percent of the population has some sleep apnea, and half of those cases are serious enough to warrent treatment.Dement, William and Vaughan, Christopher. The Promise of Sleep p. 169
Obstructive Sleep Apnea occurs more frequently in people with Down Syndrome than in the general population. A little over 50% of all people with Down Syndrome suffer from sleep apnea (de Miguel-Díez, et al 2003), and some advocate routine testing of this group (Shott, et al 2006).
The early reports of sleep apnea described individuals who were very severely affected, often presenting with severe hypoxemia, hypercapnia and congestive heart failure. Tracheostomy was the recommended treatment and, though it could be life-saving, post-operative complications in the stoma were frequent in these very obese and short-necked individuals.
The management of obstructive sleep apnea was revolutionized with the introduction of continuous positive airway pressure (CPAP), first described in 1981 by Colin Sullivan and associates in Sydney, Australia. The first models were bulky and noisy but the design was rapidly improved and by the late 1980s CPAP was widely adopted. The availability of an effective treatment stimulated an aggressive search for affected individuals and led to the establishment of hundreds of specialized clinics dedicated to the diagnosis and treatment of sleep disorders. Though many types of sleep problems are recognized, the vast majority of patients attending these centers have sleep disordered breathing.
Most people with sleep apnea have obstructive apnea, in which the person stops breathing during sleep due to airway blockage. Sufferers usually resume breathing within a few seconds, but periods of as long as sixty seconds are not uncommon in serious cases. It is more common amongst people who snore, who are obese, who consume alcohol, or who have anatomical abnormalities of the jaw or soft palate. However, atypical cases do occur, and the condition should not be ruled out unilaterally merely because the patient does not fit the profile.
"OSA" is caused by the relaxation of the muscles in the airway during sleep. While the vast majority of people successfully maintain a patent (open) upper airway and breathe normally during sleep, a significant number of individuals are prone to severe narrowing or occlusion of the pharynx, such that breathing is impeded or even completely obstructed (Mortimore & Douglas, 1997). As the brain senses a build-up of carbon dioxide, airway muscles are activated which open the airway, allowing breathing to resume but interrupting deep sleep.
Recurrent airway obstruction gives rise to the obstructive sleep apnoea (OSA) syndrome, the most common category of sleep-disordered breathing, with 2% of female and 4% of male subjects meeting the minimal diagnostic criteria for OSA of at least 10 apneic events per hour. An "event" can be either an apnea, characterised by complete cessation of airflow for at least 10 seconds, or a hypopnea in which airflow decreases by 50 percent for 10 seconds or decreases by 30 percent if there is an associated decrease in the oxygen saturation or an arousal from sleep (American Academy of Sleep Medicine Task Force, 1999). To grade the severity of sleep apnea the number of events per hour is reported as the apnea-hypopnea index (AHI). An AHI of less than 5 is considered normal. An AHI of 5-15 is mild; 15-30 is moderate and more than 30 events per hour characterizes severe sleep apnea.
These recurrent episodes of airway obstruction are associated with asphyxia, hypertension, depression, and daytime fatigue, since a transient interruption of the sleep cycle accompanies the restoration of airway patency. Most sufferers are not aware of these events, and are informed of the symptoms by their sleep partner. The apneic episodes are thought to account for the clinical sequelæ (symptoms that arise from a particular condition), which include increased incidence of chronic hypertension, a 700% rise in road traffic accidents, excessive daytime somnolence (similar, but unrelated to narcolepsy), social and family disruption, and cardiac arrhythmias and morbidity (Strollo, Jr. & Rogers, 1996). Obstruction of the upper airway may also be a cause of or may contribute to sudden infant death syndrome (SIDS) (Mathur & Douglas, 1994).
The most accurate diagnostic tool, polysomnography, can establish the diagnosis and assist in identifying the type of sleep apnea present. This test is usually done overnight in specialized sleep laboratories, either freestanding or in a hospital. Portable sleep recording systems that can perform unattended polysomnography in the patient's home or hospital bed are used in certain circumstances, but in-laboratory testing with a technician present remains the gold standard and is required by many insurers, (eg. Medicare of the United States) before they will pay for treatment of the condition.
Screening devices, measuring fewer parameters than traditional polysomnography, are sometimes used to determine if patients are likely to test positive for obstructive sleep apnea. The value of such devices is the subject of debate and study among sleep medicine professionals. Some feel that such devices can reduce costs and conserve resources, while others feel that the devices are unnecessary: a positive result leads to polysomnography anyway, while a negative result cannot be trusted if the patient still complains of symptoms.
While the face mask makes some sufferers hesitant to try treatment, many patients find that the initial difficulty of adapting to the machine is quickly surpassed by improved, deeper sleep. In addition, the introduction of masks that resemble an oversized oxygen cannula have been better tolerated by some users. The vast majority of patients are surprised to find that they tolerate the mask fairly easily and sleep well while wearing it. Despite their nature as "air compressors", modern CPAP machines are extremely quiet.
These treatments are often used with accompanying humidification, as some users experience a drying effect of the airway and mucous membranes. In the United States, these machines require a prescription. A sleep study is first done to determine what kind of treatment is needed, and to determine the proper settings for the nPAP device.
A second type of physical intervention, a Mandibular advancement splint (MAS), is sometimes prescribed for mild or moderate sleep apnea sufferers. The device is a mouthguard similar to those used in sports to protect the teeth. For apnea patients, it is designed to hold the lower jaw slightly down and forward relative to the natural, relaxed position. This position holds the tongue farther away from the back of the airway, and may be enough to relieve apnea or improve breathing for some patients.
The FDA accepts only 16 oral devices for the treatment of sleep apnea. A listing is available at their website
Oral appliance therapy is less effective than CPAP, but is more 'user friendly'. Side-effects are common but rarely is the patient aware of them.
Oral administration of the methylxanthine theophylline (chemically similar to caffeine) can reduce the number of episodes of apnea, but can also produce side effects such as palpitations and insomnia. Theophylline is generally ineffective in adults with OSA, but is sometimes used to treat Central Sleep Apnea (see below), and infants and children with apnea.
In 2003 and 2004, some neuroactive drugs, particularly a couple of the modern-generation antidepressants including mirtazapine, have been reported to reduce incidences of obstructive sleep apnea. As of 2004, these are not yet frequently prescribed for OSA sufferers.
When other treatments do not completely treat the OSA, drugs are sometimes prescribed to treat a patient's daytime sleepiness or somnolence. These range from stimulants such as amphetamines to modern anti-narcoleptic medicines. The anti-narcoleptic modafinil is seeing increased use in this role as of 2004.
In some cases, weight loss will reduce the number and severity of apnea episodes, but for most patients overweight is an aggravating factor rather than the cause of OSA. In the morbidly obese, a major loss of weight (such as what occurs after bariatric surgery) can sometimes cure the condition.
This is not a common mode of treatment for OSA patients as of 2004, but it is an active field of research.
See prevalence of different apneas in: *. For men aged 65 to 100 the prevalence is very common, nearly the same as for obstructive apnea.
Overdoses of opiates, such as heroin and morphine, kill by inducing a severe central apnea; these drugs are thus called "respiratory depressants". Central sleep apnea is more common at high elevations.
A combination of Obstructive and Central Apnea is called Mixed Apnea.
Abnormal respiration | Sleep disorders | Medical conditions related to obesity
Schlafapnoe-Syndrom | Uneapnoe | Υπνική άπνοια | Síndrome de apnea-hipopnea durante el sueño | Apnée du sommeil | Slaapapneu | 睡眠時無呼吸症候群 | Søvnapné | Apnéia do sono | Uniapnea
This article is licensed under the GNU Free Documentation License.
It uses material from the
"Sleep apnea".
Home Page • arts • business • computers • games • health • hospitals • home • kids & teens • news • physicians • recreation• reference • regional • science • shopping • society • sports • world